42 matches for your search in the start-up spotlight
rss
Shorten research and development time for cancer drugs from 3 years to 12 months and significantly reduce development costs
24-Mar-2025
The German-Swiss biotechnology start-up BioCopy has secured new capital of 8 million euros. This sum is an important step for the company on its mission to produce more effective cancer drugs in the shortest possible time and at significantly lower costs. The company is supported by a group of ...
10-Mar-2025
Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187.0 million Series A financing round. This financing was led by Frazier Life Sciences with ...
03-Mar-2025
Improving treatment recommendations for colorectal cancer patients: This is the aim of a collaborative project between the University of Bonn, the company ESQlabs and the University Hospital Bonn (UKB), funded by the Federal Ministry of Education and Research. "ISPOT-K" combines organoids derived ...
Neogap Therapeutics' PIOR technology identifies targets for personalised liver cancer immunotherapies
17-Feb-2025
A new study published in the scientific journal Gut examines how immune system T cells respond to tumours in patients with advanced liver cancer (HCC). Using Neogap Therapeutics' PIOR® software platform, the researchers have identified tumour-specific mutations, which may contribute to the ...
First successful simultaneous 10-target multiplex-screening
09-Jan-2025
QUANTRO Therapeutics, a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for ...
Research findings have been transferred to the start-up biotech company BioRevert
07-Jan-2025
Despite the development of numerous cancer treatment technologies, the common goal of current cancer therapies is to eliminate cancer cells. This approach, however, faces fundamental limitations, including cancer cells developing resistance and returning, as well as severe side effects from the ...
“Our method, which involves equipping blood cells with a kind of protective shield and then targeting and removing diseased cells, smooths the way for treatments that could not have been used in that way before”
17-Dec-2024
Start-up Cimeio Therapeutics intends to pave the way for gentler and more efficient treatments for diseases such as blood cancer. The company, a spin-off of the University of Basel, has just concluded an important collaboration agreement: Cimeio is joining forces with the pharmaceutical firm ...
SRTD biotech secures seed financing
18-Nov-2024
Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient ...
28-Oct-2024
QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company is entering into a strategic research collaboration with the group of Dr. Johannes Zuber, a world-leading expert in functional genetics and one ...
16-Oct-2024
invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, announced that the company has raised €8.2 million in a Series A fundraising that includes strong participation from existing shareholders and Ligand Pharmaceuticals. Ligand recently acquired APEIRON, the ...
